Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. - Wikidata - wikimedia - TriplyDB

Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

http://www.wikidata.org/entity/Q37600695

about

DNA Damage: A Main Determinant of Vascular Aging PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice.Levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy Profibrinolytic effect of the epigenetic modifier valproic acid in man.Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?Inhibitory effects of C-type natriuretic peptide on the differentiation of cardiac fibroblasts, and secretion of monocyte chemoattractant protein-1 and plasminogen activator inhibitor-1.miRNA-130b is required for the ERK/FOXM1 pathway activation-mediated protective effects of isosorbide dinitrate against mesenchymal stem cell senescence induced by high glucose.Long-term effects of maternal citrulline supplementation on renal transcriptome prevention of nitric oxide depletion-related programmed hypertension: the impact of gene-nutrient interactions.Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis Nitric oxide prevents alveolar senescence and emphysema in a mouse model.Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.In vivo evidence for an endothelium-dependent mechanism in radiation-induced normal tissue injury.Proton Pump Inhibitors Accelerate Endothelial Senescence Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review.PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.Drug discovery in renal disease--towards a more efficient framework.Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence.A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the Strong Heart Study.Plasminogen activator inhibitor-1 is associated with leukocyte telomere length in American Indians: findings from the Strong Heart Family Study.Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease.Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.A null mutation in SERPINE1 protects against biological aging in humans.The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1.Telomere Biology and Thoracic Aortic Aneurysm.Downregulation of the Apelinergic Axis Accelerates Aging, whereas Its Systemic Restoration Improves the Mammalian Healthspan.Stress granules counteract senescence by sequestration of PAI-1.Vascular Senescence in Cardiovascular and Metabolic Diseases.Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model.Mesenchymal stem cells confer resistance to doxorubicin-induced cardiac senescence by inhibiting microRNA-34a.

P2860

Q26746962-3AF86348-977C-4AE2-88CB-D79AEC11B5E5 Q33627219-508B5225-2854-4BC5-BBE8-58B4622669AD Q34292483-091FE245-141D-48DE-B455-D26349C00F19 Q34306821-61EBB0FE-368A-428F-96A8-38E110BB315B Q34501403-AD24FC8A-86DC-4F71-BAE8-93A9A7E8CD8E Q34540845-7E976011-0281-4D7F-B19E-687AE38AF0E9 Q34599029-7129CF35-99A8-436A-82B6-7D5A5354B254 Q34835432-AC29C0DA-D1DB-4EF0-B4F4-A1B5C2EBC233 Q35542637-865D13B9-0CAD-45E8-A7C8-BED8ECDA8C97 Q35574454-AED72E67-4999-4E74-ABAB-60C4053F4DEF Q35711136-9EE9AC72-0523-43C6-9528-26FCFB49ABD7 Q35764595-59F4A046-03F2-48AA-B017-AEA967C5FAE9 Q36039605-4E9FEF21-4F5D-4A1D-8479-C7BC4562055C Q36214635-EB415D24-09A9-4AC4-8C93-E4889EAF972F Q36221698-4C0D9EE2-F4A4-44B6-AD19-DA8C754997FD Q36993998-887A5AFB-1255-42FA-B398-6753D92E17FB Q37284133-5736C447-AD7B-42E3-91FF-42A4529BB396 Q37668960-55504BE2-5944-4D2E-B41F-5946EF49EB23 Q38197042-E3F2341A-3C75-4617-A8C8-1D4F433D1976 Q39344951-AE76B618-2B39-4EA3-908E-D84CFA4D6BA7 Q39658243-CACC233B-4DFF-413E-B767-4E8517E4F460 Q40256787-60B9CDFE-9A36-4351-8B0D-B0345CB17768 Q40257604-F3510022-5FAD-4C5C-8225-F7B93D681AD1 Q42334889-922743B4-6637-44A0-BA17-8A2917EA1E3B Q42738253-CADC049B-C9CC-4D78-9AE6-B807E2B309F6 Q45751815-4201A2DC-0475-4690-863A-F43916633C10 Q45868567-0DBABAD7-48C9-49B5-A8D8-6B98681B0774 Q45874700-906DD6EA-DB10-4BB0-90AF-A547D3BC365D Q46282340-C47FDFEE-15BA-4A0A-851D-C973EE30C149 Q47265486-D7FD72B5-D6AE-48CD-8620-B9B6D634F4D4 Q50104995-44980865-E034-4353-AE57-F05990529DD6 Q51758735-5D889131-8E01-4275-91E4-AFA29A7F62B1 Q51761509-0A198096-F463-4C90-AA5D-BB56858FF9A9 Q53106656-9C21C3DD-08B4-4A11-9E1B-14F057F69664 Q55312032-A9DF7702-4BEF-4585-B252-66CEA4E0818C

P2860

Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

http://www.wikidata.org/entity/Q37600695

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Plasminogen activator inhibito ...... nsion and vascular senescence.

@en

Plasminogen activator inhibito ...... nsion and vascular senescence.

@nl

type

label

Plasminogen activator inhibito ...... nsion and vascular senescence.

@en

Plasminogen activator inhibito ...... nsion and vascular senescence.

@nl

prefLabel

Plasminogen activator inhibito ...... nsion and vascular senescence.

@en

Plasminogen activator inhibito ...... nsion and vascular senescence.

@nl

P1433

Q37600695-AA041052-3AFC-43DC-8228-50F1F067BFBE

P1476

Q37600695-5106D41F-0E4F-460E-943F-139C25D01DC3

P2093

Q37600695-3079CB0A-12CF-40BE-AFA3-75CAEB1643AE

Q37600695-31B16520-DC35-43E1-8822-2B0B7248E5C7

Q37600695-3FD2345D-6076-485A-B104-C6F9BC6ED0CF

Q37600695-44780FCF-1C4C-49AC-B6EF-E245EB04D78F

Q37600695-5D4435EC-28B6-4816-AD81-7AFB7C33CBE8

Q37600695-6C2CEF7F-F893-476A-9044-4AA1CFDC7DD7

Q37600695-9CF171A0-40DF-48D3-A6C7-164D2A4CC39C

Q37600695-9F5266DE-B49E-454D-9393-18AF5CCE8990

P2860

Q37600695-0D4C8B6E-A1D2-4672-BA46-8C6C00A79A44

Q37600695-0D7C2547-B3C6-4442-A8FF-D6239B3B73C5

Q37600695-12A7D26B-7BA8-4D05-87B9-9F43033AFA82

Q37600695-2D9AB04F-253A-4FFB-A20B-7D3595EED1EF

Q37600695-2F76E342-0772-4A16-93CC-3FBC9808377E

Q37600695-31AFEB21-BC6E-47A2-BF61-1B2B24C5AA87

Q37600695-34EB595F-711A-4027-A0F3-AEE3F0727211

Q37600695-3B4BEF9C-AAE7-46F9-91AB-29E285A87D17

Q37600695-46CB9722-CD0D-4870-B8B2-EDFDACAE9363

Q37600695-5A2D4BCB-7FA8-45FB-8235-7406398E9379

P304

Q37600695-2343006D-BA62-4CDC-8599-FC04BA676F74

P31

Q37600695-DB48B908-2B37-4DCA-8E3F-2EB5F36D8033

P356

Q37600695-A1E25353-903C-44E5-8E09-ACE0AD989429

P407

Q37600695-BE8593DE-6EA2-46E4-84F2-F5FB2778AB1E

P433

Q37600695-1B58FEBC-D542-4005-BCD5-BD3F58870076

P478

Q37600695-0039E740-F03F-4BF4-8BEF-85F345A67925

P50

Q37600695-427E4CED-E3EF-4A1B-80C2-EB6F8C8A4DE7

Q37600695-85F50354-721E-4805-8453-EFA065C6E126

P577

Q37600695-DE3FE620-E99E-494D-BD39-CE1063A8F4E6

P5875

Q37600695-F2D10BF2-F628-40BD-9812-9D7B6930982B

P698

Q37600695-F84242E4-1B09-4332-8A42-48C75F952E0D

P921

Q37600695-4FC86A33-680F-48D6-9702-63240C2BA4EA

P932

Q37600695-141D3302-A5D5-4D37-8A54-2EE04D49AD16

P356

CIRCULATIONAHA.113.003192

P1433

P1476

Plasminogen activator inhibito ...... nsion and vascular senescence.

@en

P2093

Amanda E Boe

http://www.w3.org/2001/XMLSchema#string

Christine E Kamide

http://www.w3.org/2001/XMLSchema#string

Danielle McAnally

http://www.w3.org/2001/XMLSchema#string

David Terry

http://www.w3.org/2001/XMLSchema#string

Douglas E Vaughan

http://www.w3.org/2001/XMLSchema#string

Mesut Eren

http://www.w3.org/2001/XMLSchema#string

Sheila B Murphy

http://www.w3.org/2001/XMLSchema#string

Toshio Miyata

http://www.w3.org/2001/XMLSchema#string

P2860

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

Nitric oxide synthases in mammals

Telomere measurement by quantitative PCR

Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system

Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis

Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland.

A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.

Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence

Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.

Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes

P304

2318-2324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.113.003192

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Atsuhiko Ichimura

P577

2013-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257350547

http://www.w3.org/2001/XMLSchema#string

P698

24092817

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

3933362

http://www.w3.org/2001/XMLSchema#string